InvestSMART

Imricor Medical Systems Inc (ASX:IMR)

ALERT: Price-sensitive ASX Announcement for IMR
Current share price for IMR : $1.675 0.33 (24.54%)+
Announcement
Release
26 Aug 2025 8:06AM
Price at Release
$1.345
Full Release
download
Summary
Imricor Medical Systems Inc. released its half-year financial results for the period ending 30 June 2025. The company reported a revenue of $196,000, which was temporarily impacted by participation in the VISABL-AFL clinical trial. Imricor anticipates a revenue increase as trials conclude and the pipeline converts, especially following anticipated US FDA approval. Imricor's balance sheet remains robust with $50.3 million cash at bank. The company has made significant advancements including successful regulatory submissions and approvals, such as the 2nd Premarket Approval Module to the US FDA and CE Mark approval under MDR for its second-generation products. Imricor is pioneering in the iCMR cardiac ablation field, integrating real-time MRI guidance with its ecosystem of devices, marking a transformative leap in the electrophysiology market. The company also highlighted its growth strategies, including VISABL-VT and VISABL-AFL trials and expansion into new geographies.
Key Points
  • Imricor reported $196,000 in revenue for 1H 2025.
  • Financial results impacted by VISABL-AFL clinical trial participation.
  • Robust balance sheet with $50.3 million cash at bank.
  • Successful US FDA 2nd Premarket Approval Module submission.
  • CE Mark approval under MDR for second-generation products.
  • Imricor is leading in iCMR cardiac ablation with real-time MRI integration.
  • Anticipated growth post-US FDA approval and trial completions.
  • Expansion into new geographies and execution of key trials.
  • Strong sales pipeline growth in Europe.
  • New iCMR labs under construction in Saudi Arabia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.